Home > Search Results
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Treats hepatitis B and HIV infection. This medicine will not cure hepatitis B, HIV, or AIDS, but it may help slow the progress of the disease.

UsesSide effectsLatest evidence reviewsResearch summaries for consumersBrand names

Results: 1 to 20 of 95

Combination therapy with lamivudine and HBIG versus lamivudine monotherapy in prevention of hepatitis B virus recurrence after liver transplantation: a systematic review

Bibliographic details: Jiang Z, Jiang J.  Combination therapy with lamivudine and HBIG versus lamivudine monotherapy in prevention of hepatitis B virus recurrence after liver transplantation: a systematic review. Chinese Journal of Evidence-Based Medicine 2010; 10(8): 864-871

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

Lamivudine versus lamivudine-thymosin alpha-1 combination therapy for HBeAg positive chronic hepatitis B: a systematic review

Bibliographic details: Hu H B, Xu T, Cheng K, Su N, Tang Y.  Lamivudine versus lamivudine-thymosin alpha-1 combination therapy for HBeAg positive chronic hepatitis B: a systematic review. Chinese Journal of Evidence-Based Medicine 2009; 9(8): 904-909

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

Interferon-[alpha] combined with lamivudine for children with hepatiitis B: a meta-analysis

Bibliographic details: Jian N, Fang ZQ, Chen QM, Chen QF.  Interferon-[alpha] combined with lamivudine for children with hepatiitis B: a meta-analysis. Chinese Journal of Evidence-Based Medicine 2013; 13(8): 1013-1017

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Prophylactic lamivudine to improve the outcome of breast cancer patients with HBsAg positive during chemotherapy: a meta-analysis

Bibliographic details: Zheng Y, Zhang S, Grahn HM, Ye C, Gong Z, Zhang Q.  Prophylactic lamivudine to improve the outcome of breast cancer patients with HBsAg positive during chemotherapy: a meta-analysis. Hepatitis Monthly 2013; 13(4): e6496

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis

Bibliographic details: Katz L H, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R.  Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. Journal of Viral Hepatitis 2008; 15(2): 89-102

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2008

Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials

This review evaluated the efficacy and safety of lamivudine for the treatment of hepatitis B following renal transplantation. The authors found that rates of virological and biochemical response to lamivudine were high and the drug was well tolerated, but lamivudine resistance was frequent after prolonged therapy. The conclusions are based on evidence from uncontrolled studies and, therefore, may not be reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2004

Comparative meta-analysis of adefovir dipivoxil monotherapy and combination therapy of adefovir dipivoxil and lamivudine for lamivudine-resistant chronic hepatitis B

OBJECTIVES: The aim of the current study was to compare the effectiveness of adefovir dipivoxil (ADV) monotherapy with that of combination ADV and lamivudine (LAM) therapy in the treatment of LAM-resistant chronic hepatitis B (CHB).

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus

This well-conducted review evaluated the effectiveness of rescue combination therapy with adefovir dipivoxil plus lamivudine compared with adefovir dipivoxil monotherapy in lamivudine-resistant chronic hepatitis B patients; it found the combination of adefovir dipivoxil plus lamivudine to be superior in inhibiting hepatitis B virus replication and preventing drug resistance. This conclusion is likely to be reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

Comparison of the efficacy of lamivudine plus adefovir versus entecavir in the treatment of lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis

BACKGROUND: Hepatitis B virus infection remains 1 of the major health threats worldwide. Currently, lamivudine plus adefovir combination therapy or entecavir monotherapy is usually used for the treatment of patients with lamivudine-resistant chronic hepatitis B (CHB). However, there are few systematic comparisons between the efficacy of lamivudine plus adefovir and the efficacy of entecavir in the treatment of these patients.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis

The authors concluded that among HBeAg-positive patients, thymosin alpha-1 and lamivudine combination therapy may be more effective than lamivudine monotherapy with superior rates of biochemical and virological responses and HBeAg seroconversion. The conclusions reflect the evidence presented and are likely to be reliable, but should be interpreted with caution given the limited quality of included studies.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

Evaluation on HBeAg conversion time when treating chronic hepatitis B patients with combination of lamivudine and traditional Chinese medicine

OBJECTIVE: To evaluate the effect of the combined use of traditional Chinese medicine and lamivudine (LMD) in treating chronic hepatitis B patients, and to follow the serological response for six months or longer.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2008

Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis

This review concluded that lamivudine plus hepatitis B immunoglobulin effectively reduced hepatitis B virus recurrence and YMDD mutant incidence in liver transplant patients, but did not improve patient or graft survival compared with lamivudine monotherapy. Limitations with the included trials, such as trial quality and the data synthesis, suggest that the authors' conclusions should be interpreted with caution.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis

The review concluded that lamivudine plus adefovir was more effective and longer lasting than entecavir monotherapy in the treatment of lamivudine-resistant patients with chronic hepatitis B. The limited number patients and poor quality studies, along with no significant benefit shown in the analyses for virological response (the primary outcome), mean that the authors' conclusions may not be reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

Lamivudine and interferon versus lamivudine monotherapy for HBeAg-positive hepatitis B treatment: a meta-analysis of randomized, controlled trials

Lamivudine in combination with PEGylated interferon had better outcomes than lamivudine monotherapy, but not PEGylated interferon monotherapy. Lamivudine in combination with conventional interferon had better outcomes than lamivudine monotherapy or conventional interferon monotherapy. The possibility of reviewer error or bias and a conclusion that extended beyond the data presented mean that the conclusions should be treated with some caution.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2007

Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review

BACKGROUND: Chronic viral hepatitis B remains a global public health concern. Currently, several drugs, such as lamivudine and telbivudine, are recommended for treatment of patients with chronic hepatitis B. However, there are no conclusive results on the comparison of the efficacy of lamivudine (LAM) and telbivudine (LdT) in the treatment of chronic hepatitis B.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection

BACKGROUND: Reactivation of hepatitis B virus infection in asymptomatic hepatitis B surface antigen carriers undergoing chemotherapy or immunosuppressive therapy is a well-documented and potentially fatal complication. Data supporting the use of lamivudine for primary prophylaxis have emerged, but its use remains controversial and is not standardized.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2006

Interferon and lamivudine combination therapy versus lamivudine monotherapy for hepatitis B e antigen-negative hepatitis B treatment: a meta-analysis of randomized controlled trials

BACKGROUND: It has been demonstrated that only a minority of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) obtain a sustained response after either interferon (IFN) or nucleos(t)ide analogue monotherapy. Therefore, combination therapy of drugs with synergistic antiviral effects was proposed to have a sustained response in these patients. We compared the effect and safety of lamivudine monotherapy and its combination with IFN including conventional interferon (CON-IFN) and pegylated interferon (PEG-IFN) for HBeAg-negative CHB patients.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

Meta-analysis of the short-term effects of lamivudine treatment for severe chronic hepatitis B

PURPOSE: To evaluate the short-term effect of lamivudine (LMV) treatment for severe chronic hepatitis B.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Comparative efficacy of Lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials

INTRODUCTION: Lamivudine and emtricitabine are considered equivalent by several guidelines, but evidence of comparable efficacy is conflicting.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance

The review found that lamivudine prophylaxis was associated with a significant decline in hepatitis B virus (HBV) reactivation and a trend in reduction of HBV-related deaths in lymphoma patients who received cancer chemotherapy. Limitations of the review methodology and reporting mean that the reliability of the conclusions is uncertain.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

Systematic Reviews in PubMed

See all (217)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...